Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
For patients with type 2 diabetes and Hashimoto's, options include: Semaglutide (Ozempic) : Once-weekly injection with robust efficacy for glycemic control, weight loss, and cardiovascular risk reduction Semaglutide (Rybelsus) : Oral daily tablet requiring careful timing with levothyroxine Dulaglutide (Trulicity) : Once-weekly injection with established cardiovascular benefits Liraglutide (Victoza) : Daily injection with cardiovascular risk reduction and extensive long-term safety data Tirzepatide (Mounjaro) : Once-weekly injection combining GLP-1 and GIP receptor agonism, showing superior efficacy in clinical trials For patients with obesity and Hashimoto's, FDA-approved options include: Semaglutide (Wegovy) : Once-weekly injection at higher doses than Ozempic Liraglutide (Saxenda) : Daily injection Tirzepatide (Zepbound) : Once-weekly injection with significant weight loss efficacy The presence of Hashimoto's thyroiditis does not inherently favor one GLP-1 medication over another
Follow the steps below to obtain your Letter of Medical Necessity (LMN) and claim your HSA/FSA savings
Multiple imputation of discrete and continuous data by fully conditional specification
These enzymes modulate the cAMP/PKA/CREB signaling cascade, where cAMP activates PKA, leading to the phosphorylation of CREB at Ser133 and DARPP-32 at Thr34
